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Diabetic ketoacidosis (DKA) and hypertonic hyperglycemia
syndrome (HHS), acute and potentially life-threatening complications
of diabetes mellitus, are frequently the result of a precipitating illness
or nonadherence to treatment. This study aimed to report one success-
ful case of DKA cocurrent HHS, with blood glucose level reaching up to
1969 mg/dL, treated with continuous renal replacement therapy
(CRRT), and to provide a review of the medical literature. The clinic
and hospital medical records of 1 subject with type 2 diabetes mellitus
and unexplained DKA cocurrent HHS are reviewed. An electronic
MEDLINE search of relevant medical literature published from 2000 to
2016 was performed. In addition, the reference lists of the identiﬁed
articles and other sources, such as textbook chapters and meeting
abstracts, were reviewed for related publications. To date, there have
been no reports on patientswith serious conditionwhose blood glucose
level was up to 1881 mg/dL and who underwent CRRT treatment of
acute kidney injury caused by DKA and HHS. The case provides a new
method for DKA or HHS treatment for patients who have very high
level of blood glucose that cannot only use insulin glargine treatment.
In conclusion, CRRT can be used not only to treat diabetic nephropathy
but also to treat DKA or HHS to reduce blood glucose.
A 47-year-old man without a history of diabetes presented to the
emergency department (ED) after an unexpected 5-hour coma. Accord-
ing to his wife, 1 week before ED presentation, he had become very
thirsty and had been drinking huge amounts of water. There was no
fever, cough, rhinorrhea, or diarrhea, and no family member or friend
who had been ill. He had not been diagnosed as having diabetes ever.
Hence, he had been managed with insulin or agent. Also, he did not
check his blood glucose at home regularly. When he was found uncon-
scious, his wife called emergencymedical services. On emergencymed-
ical services arrival, the patient was noted to have breath that smelled
like apples and the blood glucose level determined by ﬁnger-stick mea-
surement was above the upper limit of the reference range when cali-
brated with the use of a glucometer, and saline by intravenous drip
was given. On arrival at the ED, ﬁnger-stick blood glucose was still
high, and the laboratory tests showed the following: blood urea☆ Disclosure statement: The authors have nothing to disclose.
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μmol/L); and uric acid, 630 μmol/L. A venous blood gas analysis revealed
a pH of 7.12, partial pressure of carbon dioxide (PCO2) of 27mmHg, par-
tial pressure of oxygen (PO2) of 140 mm Hg, and bicarbonate level of
11.3 mmol/L. Sodium level was 122 mmol/L; potassium, 6.1 mmol/L;
chloride 89, mmol/L; and blood lactic acid level, 3.1 mmol/L. The anion
gap was 25 mmol/L. He received 0.15 units of regular insulin per kilo-
gram of body weight per hour by intravenous infusion en route, as
well as an additional 500 mL of normal saline 0.9% sodium. Then he
was transferred to the endocrine department, and he was monitored
closely; ﬁnger-stick blood glucose was checked every hour. Laboratory
tests showed a blood glucose level of 1969 mg/dL, and a venous blood
gas analysis revealed a pH of 7.14, PCO2 of 22 mm Hg, PO2 of 94 mm Hg,
and bicarbonate level of 7.5 mmol/L. Sodium level was 121 mmol/L; po-
tassium, 5.9mmol/L; chloride, 91mmol/L; and blood lactic acid level, 2.9
mmol/L. The anion gap was 22 mmol/L. Other laboratory test results
included a blood urea nitrogen level of 82.1mg/dL (28.9mmol/L); creat-
inine, 3.5 mg/dL (317 μmol/L); and uric acid, 663 μmol/L. Serum amylase
was 419 U/L and serum lipase was 3654 U/L. The manifestation of elec-
trocardiogram was as follows: sinus tachycardia and left-axis deviation.
Chest radiography shows pulmonary infection. The result of a urine
test was 3+ for glucose; it was suspiciously positive for ketones and
was negative for albumin. He received 0.1 units of regular insulin per ki-
logramof bodyweight per hour by intravenous infusion en route, aswell
as 1000 mL per hour of normal saline 0.9% sodium. At the same time, he
underwent continuous renal replacement therapy (CRRT) about 4 hours.
After that the patient was dysphoric, and the reviewed laboratory tests
showed a blood glucose level of 374.4 mg/dL, and a venous blood gas
analysis revealed a pH of 7.24, PCO2 of 31.2 mm Hg, PO2 of 120 mm Hg,
and bicarbonate level of 13.5 mmol/L. The sodium level was 162
mmol/L; potassium, 3.7 mmol/L; chloride, 132 mmol/L; and blood lactic
acid level, 0.9 mmol/L. The anion gap was 12 mmol/L. Blood urea nitro-
gen level was 64.4 mg/dL (23 mmol/L); creatinine, 3.3 mg/dL (305
μmol/L); and uric acid, 591 μmol/L. Serum amylase was 444 U/L and
serum lipasewas 1071U/L. Then hewas given regular insulin, potassium
supplements, and ﬂuid therapy. Four days after treatment, the patient
came round and the laboratory tests showed the following: blood glu-
cose level, 306 mg/dL; pH 7.34; sodium level, 144 mmol/L; potassium,
4.1 mmol/L; chloride, 112 mmol/L; and blood lactic acid level,
1.2 mmol/L. The anion gap was 9 mmol/L. Other laboratory test results
included a blood urea nitrogen level of 27.8 mg/dL (9.96 mmol/L),
creatinine of 2.2 mg/dL (203 μmol/L), and uric acid of 305 μmol/L.
Serum amylase was 103 U/L and serum lipase was 681 U/L. Then he
was auto-discharged.
The incidence of severe complications of diabetes has increased in
recent years. Diabetic ketoacidosis (DKA) is more common in subjectsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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malities in serum potassium are common in DKA due to increased plas-
ma tonicity, which results in intracellular water and potassium shifts
into the extracellular space. Also, protein catabolism with resultant po-
tassium shifts into the extracellular space decreased potassium reentry
into the cell secondary to insulinopenia, and signiﬁcant renal potassium
losses as a result of osmotic diuresis and ketonuria contribute to potas-
sium dyshomeostasis. Progressive volume depletion leads to decreased
glomerular ﬁltration rate and a greater retention of glucose and
ketoanions in plasma which elevates plasma tonicity. Thus, a consider-
able proportion of patients with DKA have concomitant hypertonicity
[2,3]. Hyperglycemic hyperosmolar syndrome (HHS) is characterized
by hyperglycemia and hyperosmolality with or without metabolic
acidosis [4,5]. It is typically associated with type 2 diabetes mellitus
(T2DM) [6]. The prognosis of HHS is worse than that of DKA. Hypergly-
cemic hyperosmolar syndromemight cause thrombosis, rhabdomyoly-
sis, renal failure, and irreversible cardiac arrhythmias [7–9]. Herein, we
report a patient newly diagnosed as having T2DM complicated with
DKA and HHS, and treated with CRRT to lower the blood glucose level.
The relevant literature is reviewed, and the experiences of identifying
and treating such patients are summarized so as to aid in ﬁnding a
useful therapeutic regimen.
Continuous renal replacement therapy was ﬁrst introduced in 1977
as a mechanism to remove ﬂuid in volume-overloaded patients who
were resistant to diuretics [10]. It is a widely used therapeutic tool for
critically ill patients with severe acute kidney injury. A variety of
methods can be used to achieve adequate clearance of solute and toxins
while achieving precise control of extracellular ﬂuid volume. These
methods use the concepts of diffusion, convection, or a combination of
the 2, with the goal of eliminating uremia, maintaining ﬂuid status,
and achieving electrolyte and acid-base balance. These substances
such as interleukins, complement, and other inﬂammatory mediators
can be cleared in CRRT. Glucose can easily pass across the membrane
in convective forms of CRRT. Approximately 40 to 80 g/d is lost while
a patient is on CRRT [11]. We can elect to compound our replacement
ﬂuids without glucose and noted a decrease in the amount of insulin
used to achieve glycemic control. Continuous renal replacement thera-
py improves outcomes in acute respiratory distress syndrome, limits
ﬂuid shifts in patients with cerebral edema, and decreases the inﬂam-
matory response in sepsis [12–14]. Commonly, patients who require
CRRT are themost critically ill and complex patients found in our hospi-
tals. Emerging evidence indicates that hyperglycemic emergencies in-
cluding DKA are associated with an inﬂammatory state marked by
elevation in proinﬂammatory cytokines such as tumor necrosis factor-
α, interleukins and C-reactive protein. Also, reactive oxygen species,
markers of lipid peroxidation and plasminogen activator inhibitor-1,
are elevated [15]. All of these parameters return to normal with resolu-
tion of DKA. This inﬂammatory and procoagulant state may explain the
relatively high incidence of thrombotic events in DKA. In vivo and
in vitro activation of t cells with emergence of insulin receptors has
also been demonstrated [16,17]. For severe hyperglycemia of T2DM pa-
tients with concomitant ketoacidosis and hypertonic syndrome, early
CRRT can lower blood glucose level and blood potassium, improve aci-
dosis, relieve cerebral edema, and improve the patient's survival rate.
At present, the morbidity of diabetic ketoacidosis and hypertonic
syndrome is increasing, but its mortality is declining gradually. Still,
there are a small number of patients died of cerebral edema later on.
The case for the clinical treatment of diabetes with severe ketoacidosis
and hypertonic syndrome provides a new method. In this case, the
blood glucose level is as high as 1969 mg/dL and it is very rare. At
the same time, ketoacidosis, HHS, acute renal failure, hyperkalemia,
and reactive pancreatitis occur. To maintain the patient's life, earlyPlease cite this article as: Tang Q, et al, Continuous renal replacement ther
(2016), http://dx.doi.org/10.1016/j.ajem.2016.06.061implementation of CRRT treatment takes effect on preventing cerebral
edema and later complications. The patient's blood glucose level was
down to 360 mg/dL within 24 hours, and other complications have im-
proved. This is a successful case in which CRRT treated the patient with
severe ketoacidosis and hypertonic syndrome. It is a new guidance for
diabetic patients with ketoacidosis and hypertonic syndrome.
Our observations underscore the signiﬁcant inﬂuence CRRT has on
improving the patient's survival rate. Clearly, more studies are needed
to further understand the long-term impact of CRRT.
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